On Thursday, in a statement Japan’s Fujifilm Holdings Corp said, it has signed a manufacturing contract with U.S.-based VLP Therapeutics for manufacturing a COVID-19 vaccine.
In a statement both companies said, “Fujifilm will use its manufacturing facilities and infrastructure to handle development of the vaccine for clinical trials”.
VLP’s RNA-based vaccine candidate was selected for funding by the Japan Agency for Medical Research and Development.
Ert h least decade, Fujifilm has increasingly drifted towards healthcare from its traditional photography and office solutions businesses.
Last month, it concluded a successful Phase-3 clinical trial of its Avigan drug for use in COVID-19 patients.